Diaphragm pacing systems are battery-powered pacing systems that run on electricity, are lightweight, and help in the stimulation of diaphragm nerves and muscles. They help the diaphragm in contracting, which allows the air to enter the lungs. This allows the patient to breathe normally.
Various lung pacer diaphragm pacing therapy systems(DPTS) got urgent approval from the FDA as they were needed in healthcare settings to provide mechanical ventilation for patient’s treatment. This device helps in the stimulation of phrenic nerves for diaphragm activation in adults.These patients use ventilation by using mechanics. These devices are used for temporary purposes, are transvenous, placed percutaneously, and are phrenic nerve-stimulating device. Furthermore, they are used in hospitals and other healthcare facilities by trained and qualified officials.
COVID-19 scenario analysis:
- Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs, such as hydroxychloroquine, have witnessed a dramatic surge in demand for the management of COVID-19.
- Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs as many developed countries are short of these drugs. The pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19.
- Attributed to such factors, COVID-19 is expected to have a significant impact on the market.
Top impacting factors: Market scenario analysis, trends, drivers and impact analysis
Significant increase in Invasive Mechanical Ventilation (IMV) complexities, which results in injuries related to lungs, infections, and muscle atrophy; increased frequencies of amyotrophic lateral sclerosis (ALS) and spinal cord injuries (SCI); and other benefits of diaphragm pacing therapy system (DPTS) such as dependency reduction on mechanical ventilators; betterment in breathing and speech in patients are the major factors that propel the growth of the diaphragm pacing therapy system market.
Additionally, the current crisis of global COVID-19 also increases the demand and consumption of mechanical ventilators.A rise has been observed in patients suffering from respiratory diseases due to changing lifestyle and environmental conditions, which affect the growth of the diaphragm pacing therapy system market. Furthermore, the regulatory policies also prove to be beneficial to the diaphragm pacing therapy system market.On the other hand, high prices for production and prolonged approval period are the major challenges faced by the key players of the diaphragm pacing therapy system market.
New product launches and acquisitions to boost the market
On April 14th, 2020, Lungpacer Medical got approval from the U.S. FDA. This was an emergency use authorization approval. Diaphragm pacing therapy systems are being used to help patients suffering from COVID-19. Additionally, onMay 11th, 2016, Lungpacer Diaphragm Pacing System got an approval from the Expedited Access Pathway (EPA) Designation by the U.S. FDA
Surge in usage in hospitalapplications
Hospitals, ambulatory surgical centers, and others are the major consumers of the diaphragm pacing therapy system. Amongst them, hospitals are the biggest end users in the market. This is attributed to the SCI,which help in raising the popularity, owing to the rise in number and frequency of cases related to SCIs.
Additionally, accidents or crashes during driving and sports activities also increase the admission of patients in hospitals who subsequently need diaphragm pacing therapy systems.
Key benefits of the report:
- This study presents the analytical depiction of the diaphragm pacing therapy system marketalong with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the diaphragm pacing therapy system market share.
- The current market is quantitatively analyzed to highlight the diaphragm pacing therapy system market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the diaphragm pacing therapy system market research report:
- Which are the leading market players active in the market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What are the projections for the future that would help in taking further strategic steps?
Diaphragm Pacing Therapy System Market Report Highlights
| Aspects | Details |
 By Product Type |
|
 By Applications |
|
 By Methods |
|
 By Region |
|
 Key Market Players | Boehringer Ingelheim, MedImmune, AstraZeneca, Pulmonx, Avery Biomedical Devices, Actelion, Atrotech, Arahelio, Forest, Novartis, Respironics, Pearl, Synapse Biomedical, Ikaria, Lungpacer Medical, Inc, Aeris, PneumRx |
Loading Table Of Content...
